Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Myriad Genetics, Inc. before investing.

In this article, we go over a few key elements for understanding Myriad Genetics, Inc.’s stock price such as:

• Myriad Genetics, Inc.’s current stock price and volume
• Why Myriad Genetics, Inc.’s stock price changed recently
• Upgrades and downgrades for MYGN from analysts
• MYGN’s stock price momentum as measured by its relative strength

About Myriad Genetics, Inc. (MYGN)

Before we jump into Myriad Genetics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Want to learn more about Myriad Genetics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Myriad Genetics, Inc..

Myriad Genetics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Myriad Genetics, Inc.’s stock price was $2.860.

Myriad Genetics, Inc. is down 46.74% from its previous closing price of $5.370.

During the last market session, Myriad Genetics, Inc.’s stock traded between $2.810 and $3.260. Currently, there are approximately 93.70 million shares outstanding for Myriad Genetics, Inc..

Myriad Genetics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Myriad Genetics, Inc. Stock Price History

Myriad Genetics, Inc.’s (MYGN) price is currently down 49.91% so far this month.

During the month of July, Myriad Genetics, Inc.’s stock price has reached a high of $6.430 and a low of $2.810.

Over the last year, Myriad Genetics, Inc. has hit prices as high as $8.590 and as low as $3.530. Year to date, Myriad Genetics, Inc.’s stock is down 53.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Myriad Genetics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Myriad Genetics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Myriad Genetics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Myriad Genetics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Myriad Genetics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Myriad Genetics, Inc. (MYGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Myriad Genetics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Myriad Genetics, Inc. has a weighted four-quarter relative price strength of 10.94%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how Myriad Genetics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Myriad Genetics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Myriad Genetics, Inc.’s stock price is $2.860, which is down 46.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Myriad Genetics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.